Angstrom Bio, Inc.

Angstrom Bio, Inc. is a biotechnology firm specializing in advanced molecular diagnostics, particularly through its innovative diagnostic platform for population-scale viral testing, including COVID-19 detection. Founded in 2019 by Carlos Santos, David States, Forrest C. , and Jonathan Feldmann, Angstrom Bio, Inc.

operates from Austin, US, and focuses on diagnostic solutions. The company raised USD 3. 00 mn in funding on June 16, 2021, led by GreyBird Ventures, bringing the total amount raised to USD 3. 00 mn.

Angstrom Bio specializes in advanced molecular diagnostics, primarily through its flagship product, the Angstrom Massively Parallel Diagnostic (AMPD) platform. This technology enables population-scale viral diagnostics, including COVID-19 detection, characterized by unprecedented throughput and unrivaled sensitivity at scale-enabling costs. The platform services healthcare providers, research institutions, and pharmaceutical companies, while also offering computational optimization for in vitro and immunization-derived antibodies, targeting areas affected by viral outbreaks and regions with robust healthcare infrastructures. Angstrom Bio's revenue model is centered around providing diagnostic services and platforms to healthcare systems and research organizations.

Engagements typically occur via direct partnerships for bulk testing services or ongoing diagnostic support. The pricing structure may involve fees for individual diagnostic tests conducted through the AMPD platform, and potential subscription models for continued access to their technologies and services, designed to meet large-scale testing needs efficiently. In June 2021, Angstrom Bio, Inc. raised USD 3.

00 mn in financing led by GreyBird Ventures. The funds will be utilized to launch a nanopore sequencing-based test for detecting various SARS-CoV variants and to develop a multiplexed panel for respiratory pathogens. The company plans to expand into new markets, although specific regions have not been detailed.